The 434(G>C) polymorphism in the eosinophil cationic protein gene and its association with tissue eosinophilia in oral squamous cell carcinomas

Journal of Oral Pathology and Medicine

Volumn 39, Issue 1, 2010, Pages 56-62

  Pereira, Michele C ^a   Oliveira, Denise T ^a   Olivieri, Eloísa H R ^b   Rogatto, Sílvia R ^b   Carvalho, André L ^c   Landman, Gilles ^d   Kowalski, Luiz P ^d  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^c Cancer Hospital of Barretos   (Brazil)

^d A C CAMARGO CANCER CENTER   (Brazil)

Author keywords

Eosinophil cationic protein; Eosinophils; Gene polymorphism; Prognosis; Squamous cell carcinoma

Indexed keywords

EOSINOPHIL CATIONIC PROTEIN;

ADULT; AGED; ALLELE; ARTICLE; ARTIFICIAL EMBOLISM; CANCER PATIENT; CANCER RECURRENCE; CONTROLLED STUDY; DEMOGRAPHY; DISEASE FREE SURVIVAL; DNA CLEAVAGE; DNA SEQUENCE; EOSINOPHILIA; FEMALE; GENE AMPLIFICATION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOSITY; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MORPHOMETRICS; MOUTH CARCINOMA; NECK DISSECTION; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SQUAMOUS CELL CARCINOMA; TUMOR ASSOCIATED TISSUE EOSINOPHILIA;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CYTOSINE; DISEASE-FREE SURVIVAL; EMBOLISM; EOSINOPHIL CATIONIC PROTEIN; EOSINOPHILIA; FEMALE; FOLLOW-UP STUDIES; GENE FREQUENCY; GENOTYPE; GUANINE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; MALE; MIDDLE AGED; MOUTH NEOPLASMS; NECK DISSECTION; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; POLYMORPHISM, GENETIC; RADIOTHERAPY, ADJUVANT; SURVIVAL RATE; YOUNG ADULT;

EID: 76249088798     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/j.1600-0714.2009.00795.x     Document Type: Article

References (31)

1. Navarro S, Aleu J, Jiménez M, Boix E, Cuchillo CM, Nogués MV. The cytotoxicity of eosinophil cationic protein/ribonuclease 3 on eukaryotic cell lines takes place through its aggregation on the cell membrane. Cell Mol Life Sci 2008 65 : 324 337.
2. Carreras E, Boix E, Navarro S, Rosenberg HF, Cuchillo CM, Nogués MV. Surface-exposed amino acids of eosinophil cationic protein play a critical role in the inhibition of mammalian cell proliferation. Mol Cell Biochem 2005 272 : 1 7.
3. Molin D. Bystander cells and prognosis in Hodgkin lymphoma. Review based on a doctoral thesis. Ups J Med Sci 2004 109 : 179 228.
4. Byström J, Garcia RC, Hakansson L, et al. Eosinophil cationic protein is stored in, but not produced by, peripheral blood neutrophils. Clin Exp Allergy 2002 32 : 1082 1091.
5. Zhang J, Rosenberg HF. Sequence variation at two eosinophil-associated ribonuclease loci in humans. Genetics 2000 156 : 1949 1958.
6. Venge P, Byström J, Carlson M, et al. Eosinophil cationic protein (ECP): molecular and biological properties and the use of ECP as a marker of eosinophil activation in disease. Clin Exp Allergy 1999 29 : 1172 1186.
7. Venge P, Byström J. Eosinophil cationic protein (ECP). Int J Biochem Cell Biol 1998 30 : 433 437.
8. Jönsson UB, Byström J, Stalenheim G, Venge P. A (G→C) transversion in the 3′ UTR of the human ECP (eosinophil cationic protein) gene correlates to the cellular content of ECP. J Leukoc Biol 2006 79 : 846 851.
9. Jönsson UB, Byström J, Stalenheim G, Venge P. Polymorphism of the eosinophil cationic protein-gene is related to the expression of allergic symptoms. Clin Exp Allergy 2002 32 : 1092 1095.
10. Young JD, Peterson CG, Venge P, Cohn ZA. Mechanism of membrane damage mediated by human eosinophil cationic protein. Nature 1986 321 : 613 616.
11. Trulson A, Byström J, Engström A, Larsson R, Venge P. The functional heterogeneity of eosinophil cationic protein is determined by a gene polymorphism and post-translational modifications. Clin Exp Allergy 2007 37 : 208 218.
12. Eriksson J, Woschnagg C, Fernvik E, Venge P. A SELDI-TOF MS study of the genetic and post-translational molecular heterogeneity of eosinophils cationic protein. J Leukoc Biol 2007 82 : 1491 1500.
13. Koh GC, Shek LP, Goh DY, Van Bever H, Koh DS. Eosinophil cationic protein: is it useful in asthma? A systematic review. Respir Med 2007 101 : 696 705.
14. Sugihara R, Kumamoto T, Ito T, Ueyama H, Toyoshima I, Tsuda T. Human muscle protein degradation in vitro by eosinophil cationic protein (ECP). Muscle Nerve 2001 24 : 1627 1634.
15. Eriksson J, Reimert CM, Kabatereine NB, et al. The 434(G>C) polymorphism within the coding sequence of Eosinophil Cationic Protein (ECP) correlates with the natural course of Schistosoma mansoni infection. Int J Parasitol 2007 37 : 1359 1366.
16. Simson L, Ellyard JI, Dent LA, et al. Regulation of carcinogenesis by IL-5 and CCL11: a potential role for eosinophils in tumor immune surveillance. J Immunol 2007 178 : 4222 4229.
17. Munitz A, Levi-Schaffer F. Eosinophils: 'new' roles for 'old' cells. Allergy 2004 59 : 268 275.
18. Trulson A, Nilsson S, Venge P. The eosinophil granule proteins in serum, but not the oxidative metabolism of the blood eosinophils, are increased in cancer. Br J Haematol 1997 98 : 312 314.
19. Mingomataj EC. Eosinophil-induced prognosis improvement of solid tumors could be enabled by their vesicle-mediated barrier permeability induction. Med Hypotheses 2008 70 : 582 584.
20. Lotfi R, Lee JJ, Lotze MT. Eosinophilic granulocytes and damage-associated molecular pattern molecules (DAMPs): role in the inflammatory response within tumors. J Immunother 2007 30 : 16 28.
21. Cormier SA, Taranova AG, Bedient C, et al. Pivotal Advance: eosinophil infiltration of solid tumors is an early and persistent inflammatory host response. J Leukoc Biol 2006 79 : 1131 1139.
22. Samoszuk M. Eosinophils and human cancer. Histol Histopathol 1997 12 : 807 812.
23. Dorta RG, Landman G, Kowalski LP, Lauris JR, Latorre MR, Oliveira DT. Tumour-associated tissue eosinophilia as a prognostic factor in oral squamous cell carcinomas. Histopathology 2002 41 : 152 157.
24. Lorena SC, Dorta RG, Landman G, Nonogaki S, Oliveira DT. Morphometric analysis of the tumor associated tissue eosinophilia in the oral squamous cell carcinoma using different staining techniques. Histol Histopathol 2003 18 : 709 713.
25. Lorena SC, Oliveira DT, Dorta RG, Landman G, Kowalski LP. Eotaxin expression in oral squamous cell carcinomas with and without tumour associated tissue eosinophilia. Oral Dis 2003 9 : 279 283.
26. Ellyard JI, Simson L, Parish CR. Th2-mediated anti-tumour immunity: friend or foe? Tissue Antigens 2007 70 : 1 11.
27. Lee NA, Lee JJ. Interview with Dr. Nancy A. Lee and Dr. James J. Lee regarding Pivotal Advance: eosinophil infiltration of solid tumors is an early and persistent inflammatory host response. Interview by Helene F. Rosenberg. J Leukoc Biol 2006 79 : 1129 1130.
28. Goldsmith MM, Belchis DA, Cresson DH, Merritt WD III., Askin FB. The importance of the eosinophil in head and neck cancer. Otolaryngol Head Neck Surg 1992 106 : 27 33.
29. Goldsmith MM, Cresson DH, Askin FB. The prognostic significance of stromal eosinophilia in head and neck cancer. Otolaryngol Head Neck Surg 1987 96 : 307 318.
30. Wong DT, Bowen SM, Elovic A, Gallagher GT, Weller PF. Eosinophil ablation and tumor development. Oral Oncol 1999 35 : 496 501.
31. Horiuchi K, Mishima K, Ohsawa M, Sugimura M, Aozasa K. Prognostic factors for well-differentiated squamous cell carcinoma in the oral cavity with emphasis on immunohistochemical evaluation. J Surg Oncol 1993 53 : 92 6.